Newsticker

September 12, 2024 Corporate

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

Juni 20, 2024 Corporate

ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth

Juni 06, 2024 Corporate

ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing

Mai 28, 2024 Partnerships

Saugeen Ojibway Nation, Bruce Power, Isogen and ITM advance initiative to double capacity of IPS to produce cancer-fighting medical isotopes

Mai 07, 2024 Corporate

ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer

April 23, 2024 Corporate

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

Februar 01, 2024 Corporate

ITM Obtains Manufacturing License in the U.S.

Januar 30, 2024 Partnerships

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

View all news »

Our Company

Pipeline

In Targeted Cancer Diagnostics & Therapy

Career

Be Part Of Our
Company

Targeted
Radionuclide
Therapy

In Precision Oncology

Products

Radiopharmaceutical & Radioisotope Business

Diversity

Diversity at ITM

Diese Webseite nutzt Cookies

PASSION FOR PRECISION.

Newsticker

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth

ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing

Saugeen Ojibway Nation, Bruce Power, Isogen and ITM advance initiative to double capacity of IPS to produce cancer-fighting medical isotopes

ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

ITM Obtains Manufacturing License in the U.S.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

Inside Stories

Our Company

Pipeline

Career

Targeted
Radionuclide
Therapy

Products

Diversity

Diese Webseite nutzt Cookies

Newsticker

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth

ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing

Saugeen Ojibway Nation, Bruce Power, Isogen and ITM advance initiative to double capacity of IPS to produce cancer-fighting medical isotopes

ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

ITM Obtains Manufacturing License in the U.S.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

Inside Stories

Our Company

Pipeline

Career

Targeted Radionuclide Therapy

Products

Diversity

Targeted
Radionuclide
Therapy